Nexeon Medsystems (OTCMKTS:NXNN) versus Nexalin Technology (NASDAQ:NXL) Financial Contrast

Nexeon Medsystems (OTCMKTS:NXNN) and Nexalin Technology (NASDAQ:NXL) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Profitability

This table compares Nexeon Medsystems and Nexalin Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nexeon Medsystems	N/A	N/A	N/A
Nexalin Technology	-3,407.98%	-187.59%	-167.21%

Volatility & Risk

Nexeon Medsystems has a beta of 6.98, indicating that its share price is 598% more volatile than the S&P 500. Comparatively, Nexalin Technology has a beta of 4.24, indicating that its share price is 324% more volatile than the S&P 500.

Insider & Institutional Ownership

0.7% of Nexalin Technology shares are held by institutional investors. 61.2% of Nexeon Medsystems shares are held by company insiders. Comparatively, 24.0% of Nexalin Technology shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Nexeon Medsystems and Nexalin Technology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nexeon Medsystems	N/A	N/A	N/A	N/A	N/A
Nexalin Technology	$110,000.00	348.22	-$4.65 million	($0.64)	-4.50

Nexeon Medsystems has higher earnings, but lower revenue than Nexalin Technology.

Analyst Ratings

This is a breakdown of current ratings for Nexeon Medsystems and Nexalin Technology, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nexeon Medsystems	0	0	0	0	0.00
Nexalin Technology	0	1	0	0	2.00

Nexalin Technology has a consensus price target of $3.00, suggesting a potential upside of 4.17%. Given Nexalin Technology’s stronger consensus rating and higher probable upside, analysts plainly believe Nexalin Technology is more favorable than Nexeon Medsystems.

Summary

Nexeon Medsystems beats Nexalin Technology on 5 of the 9 factors compared between the two stocks.

About Nexeon Medsystems

Nexeon MedSystems Inc., a medical device company, develops, manufactures, and commercializes neurostimulation technology for the treatment of various neurological disorders through electrical stimulation of neural tissues. Its neurostimulation technology platform would provide treatment to patients in several neurostimulator markets, including deep brain stimulation, peripheral electrical nerve stimulation, sacral nerve stimulation, spinal cord stimulation, vagus nerve stimulation, and other neurostimulator markets. The company develops the Viant, a deep brain stimulation system for Parkinson's disease in the United States, as well as for Parkinson's disease, Essential Tremor, and Dystonia in Europe. Nexeon MedSystems Inc. was founded in 2015 and is based in Dallas, Texas.

About Nexalin Technology

Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.